Pierre Labbe, CPA, CA, ICD, will join ImmunoVaccine Inc.(IMV: CA) as chief financial officer, effective Feb. 20, 2017. In this role, Mr. Labbe will be responsible for leading the company’s financial strategy and operations, with an emphasis on expanding financing and business development operations as the Company continues to advance its clinical program and expand its pipeline.
“We are entering a transformative period of growth at Immunovaccine, and are very pleased to have a financial veteran with Pierre’s experience on our leadership team,” said Frederic Ors, Immunovaccine’s Chief Executive Officer. “His track record includes an ideal combination of financial, operational and strategic leadership, and a proven ability to identify growth opportunities in both life sciences and technology companies. He will be a great fit to lead our financial operations as we continue to advance our immuno-oncology product candidates through the clinic, and expand the applications of our DepoVax(TM) enabling technology on a global scale.”
Mr. Labbe brings to Immunovaccine more than 15 years of experience in the role of chief financial officer, having served in that capacity with, among others, Medicago Inc. and Leddartech Inc. He was an integral part of the team that negotiated the acquisition of Medicago by Mitsubishi Tanabe Pharma in 2013 for an enterprise value of $357 million Canadian dollars. He has also been responsible for numerous rounds of private and public financing, initial public offerings preparation and execution, and establishment of key strategic alliances.
“I am very pleased to join Immunovaccine as the Company moves in a forward trajectory,” said Mr. Labbe. “I am excited about the opportunity to work with Fred and his team to bolster the financial and investor base as we continue the important work of improving treatment options for the many unmet medical needs in today’s medical landscape.”
Mr. Labbe currently serves on the Boards of Directors of several publicly traded, Canadian-based companies. He earned his Bachelor’s degree from Universite Laval, and holds CA and ICD designations.
Immunovaccine Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. Immunovaccine develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVax(TM) platform, a patented delivery agent that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1/1b study with Incyte Corporation assessing lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer, as well as a Phase 2 study in recurrent lymphoma. The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV), and currently has clinical projects ongoing to assess the potential of DepoVax(TM) to address malaria and the Zika virus. Connect at www.imvaccine.com.
In the interest of full disclosure, we call the reader’s attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.